This is very puzzling and I cannot see the reasons behind this...

This is very puzzling and I cannot see the reasons behind this massive drop and can only assume that a major shareholder has decided to exit.

I have not yet had a reply from MYX regarding the change in Nexstellis reporting and I will post when and if I get a reply.

I have relistened to the CEOs presentation and I agree with Formuso that management has recommitted to previous guidance on all fronts including cashflow from continuing businesses. There was no new financial information presented. Here are some of the specific comments which caught my attention:

• "We fully expect to deliver on positive operating cashflow for the continuing businesses for the full year"
• "The security breach of Change Healthcare has been disruptive for the entire US health industry not just prescription products"
• "However for Mayne, dermatology which we drive mainly through cash, was not really disrupted"
• "We saw a clear impact on WH products but we are already back to the growth rate before the impact"
• "There was a decline in co-pay card claims particularly Nexstellis"
• "We have relaunched Nexstellis with a new marketing strategy"
• "We had stock out issues with full strength Bijuva in Feb and March due to issues with Catalent facilities but we are back fully stocked"
• "Looking at IQVIA reported units you can see the very strong growth line disrupted in Feb and March but we're back on growth from April"
• "On disintermediation we have a strong drug sourcing capability as well as contracts with over 425 pharmacies as well as our mail order pharmacy Adelaide Apothecary licensed in all 50 states"
• "The pilot programme which we deployed in the first half has worked out well and we have deployed it in the second half across all our dermatology reps to demonstrate to all physicians the value we can create for them"
• "We are putting more cash into our International business facility, which was neglected for 5 years as cash flowed to MCS, this will allow to reach markets we haven't been able to access before"
• "on outlook, we are reiterating our previous guidance"
• "We continue to execute on driving significant growth in WH portfolio in the 2hf in all our brands by leveraging our sales workforce and effectiveness in our operational improvements we've made"
• "Recently we've hired LynSullivan to lead our WH and new sales leader Tony Ramy and the results so far are looking very promising"
• "We expect to gain from ACA law where women don't have out of pocket expenses, we will see benefits from Nexstellis and Annovera for both volume and value"
• "We've seen a lot companies in WH spending their way into oblivion and we're not trying to do that here, with Lyn in place we're trying to leverage the whole franchise but also deliver profitable growth for Nextstellis"
• "Prior to Tony's arrival I can tell you that we were not executing the way we should have been with our sales team and Tony has made significant changes to the execution side"
• "So between execution and the right messaging and targeting Yaz, we have the same progesterone but have E4 a native occurring Estrogen with a range of benefits of what it does to the body"
• "We are looking to increase products that are EBITDA generating and later creating a pipeline of products"
• "The disintermediation model can be leveraged to other therapeutic areas and we have had curious interest from other small manufacturers who are affected by the margin imposed by the big 3 (I assume wholesalers)"